Epigenetic Aberrant Hypermethylation of DNA in Endometrial Cancer: Application as a Biomarker

Asuka Ono, Iori Kisu, Kouji Banno, Megumi Yanokura, Kenta Masuda, Yusuke Kobayashi, Kosuke Tsuji, Arisa Ueki, Wataru Yamagami, Hiroyuki Nomura, Nobuyuki Susumu, Daisuke Aoki

.

DOI: 10.4236/jct.2011.25082                

Abstract

Endometrial cancer is the seventh most common cancer worldwide among females and accounts for about 40% of cancers of the uterus in Japan. An increase in incidence and a reduction in onset age of this disease are also likely, which makes it important to define the pathogenesis and develop effective treatment. However, the mechanism of canceration in the endometrium is unclear and development of endometrial cancer cannot be explained only by mutations of cancer-related genes. In contrast, epigenetic analyses have shown the importance of aberrant DNA hypermethylation in the canceration mechanism. In development of type 1 endometrial cancer, breakdown of the DNA mismatch repair system plays a large role, with changes in the human mutL homologue 1 (hMLH1) gene being of most importance. Studies to detect aberrant DNA hypermethylation of cancer cells present in microscopic amounts in vivo and to apply these data to diagnosis of cancer have been started. Epigenetic changes have also been examined as a marker of sensitivity to anticancer drugs. Aberrant hypermethylation of checkpoint with forkhead-associated and ring finger (CHFR), a mitotic phase checkpoint gene, is correlated with sensitivity to treatment with microtubule inhibitors and may be a marker for the response of endometrial cancer to anticancer drugs. Epigenetic aberrant DNA methylation of other genes may also be useful as clinical biomarkers for diagnosis and treatment of endometrial cancer.

Keywords

Epigenetics, Endometrial Cancer, Aberrant DNA Hypermethylation, hMLH1, CHFR, Biomarker

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. B. Baylin and J. G. Herman, “DNA Hypermethylation in Tumorigenesis: Epigenetics Joins Genetics,” Trends in Genetics, Vol. 16, No. 4, 2000, pp. 168-174. doi:10.1016/S0168-9525(99)01971-X
[2]	M. Esteller, P. G. Corn, S. B. Baylin and J. G. Herman, “A Gene Hypermethylation Profile of Human Cancer,” Cancer Research, Vol. 61, No. 8, 2001, pp. 3225-3229.
[3]	A. D. Goldberg, C. D. Allis and E. Bernstein, “Epigenetics: A Landscape Takes Shape,” Cell, Vol. 128, No. 4, 2007, pp. 635-638. doi:10.1016/j.cell.2007.02.006
[4]	T. Ushijima, “Detection and Interpretation of Altered Methylation Patterns in Cancer Cells,” Nature Reviews Cancer, Vol. 5, No. 3, 2005, pp. 223-231. doi:10.1038/nrc1571
[5]	E. N. Gal-Yam, S. Jeong, A. Tanay, G. Egger, A. S. Lee and P. A. Jones, “Constitutive Nucleosome Depletion and Ordered Factor Assembly at the GRP78 Promoter Revealed by Single Molecule Footprinting,” PLoS Genetics, Vol. 2, No. 9, 2006, p. 160. doi:10.1371/journal.pgen.0020160
[6]	R. Appanah, D. R. Dickerson, P. Goyal, M. Groudine and M. C. Lorincz, “An Unmethylated 3’Promoter-Proximal Region Is Required for Efficient Transcription Initiation,” PLoS Genetics, Vol. 3, No. 2, 2007, p. 27. doi:10.1371/journal.pgen.0030027
[7]	P. A. Jones and S. B. Baylin, “The Epigenomics of Cancer,” Cell, Vol. 128, No. 4, 2007, pp. 683-692. doi:10.1016/j.cell.2007.01.029
[8]	K. Banno, M. Yanokura, N. Susumu, M. Kawaguchi, N. Hirao, A. Hirasawa, K. Tsukazaki and D. Aoki, “Relationship of Aberrant DNA Hypermethylation Of Cancer-Related Genes with Carcinogenesis of Endometrial Cancer,” Oncology Reports, Vol. 16, No. 6, 2006, pp. 1189-1196.
[9]	M. Kawaguchi, K. Banno, M. Yanokura, Y. Kobayashi, A. Kishimi, S. Ogawa, I. Kisu, H. Nomura, A. Hirasawa, N. Susumu and D. Aoki, “Analysis of Candidate Target Genes for Mononucleotide Repeat Mutation in Microsatellite Instability-High (MSH-H) Endometrial Cancer,” International Journal of Oncology, Vol. 35, No. 5, 2009, pp. 977-982.
[10]	T. Kanaya, S. Kyo, Y. Maida, N. Yatabe, M. Tanaka, M. Nakamura and M. Inoue, “Frequent Hypermethylation of MLH1 Promoter in Normal Endometrium of Patients with Endometrial Cancers,” Oncogene, Vol. 22, No. 15, 2003, pp. 2352-2360. doi:10.1038/sj.onc.1206365
[11]	H. J. Yang, V. W. Liu, Y. Wang, P. C. Tsang and H. Y. Ngan, “Differential DNA Methylation Profiles in Gynecological Cancers and Correlation with Clinico-Pathological Data,” BMC Cancer, Vol. 6, 2006, p. 212. doi:10.1186/1471-2407-6-212
[12]	J. Sakaguchi, S. Kyo, T. Kanaya, Y. Maida, M. Hashimoto, M. Nakamura, K. Yamada and M. Inoue, “Aberrant Expression and Mutations of TGF-Beta Receptor Type II Gene in Endometrial Cancer,” Gynecologic Oncology, Vol. 98, No. 3, 2005, pp. 427-433. doi:10.1016/j.ygyno.2005.04.031
[13]	B. P. Whitcomb, D. G. Mutch, T. J. Herzog, J. S. Rader, R. K. Gibb and P. J. Goodfellow, “Frequent HOXA11 and THBS2 Promoter Methylation, and a Methylator Pheno-type in Endometrial Adenocarcinoma,” Clinical Cancer Research, Vol. 9, No. 6, 2003, pp. 2277-2287.
[14]	M. Sasaki, M. Kaneuchi, N. Sakuragi and R. Dahiya, “Multiple Promoters of Catechol-O-Methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer,” Cancer Research, Vol. 63, No. 14, 2003, pp. 3101-3106.
[15]	H. Fiegl, C. Gattringer, A. Widschwendter, A. Schneitter, A. Ramoni, D. Sarlay, I. Gaugg, G. Goebel, et al., “Methylated DNA Collected by Tampons: A New Tool to Detect Endometrial Cancer,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, No. 5, 2004, pp. 882-888.
[16]	M. Toyota, Y. Sasaki, A. Satoh, et al., “Epigenetic Inactivation of CHFR in Human Tumors,” Proceedings of the National Academy of Sciences, Vol. 100, No. 13, 2003, pp. 7818-7823. doi:10.1073/pnas.1337066100
[17]	M. Esteller and J. G. Herman, “Generating Mutations but Providing Chemosensitivity: The Role of O6-Methylguanine DNA Methyltransferase in Human Cancer,” Oncogene, Vol. 23, No. 1, 2004, pp. 1-8.
[18]	J. S. Kim, J. W. Kim, J. Han, Y. M. Shim, J. Park and D. H. Kim, “ Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer,” Cancer Research, Vol. 66, No. 8, 2006, pp. 4049-4054. doi:10.1158/0008-5472.CAN-05-3813
[19]	T. Mori, S. R. Martinez, S. J. O’Day, et al., “Estrogen Receptor-Alpha Methylation Predicts Melanoma Progression,” Cancer Research, Vol. 66, No. 13, 2006, pp. 6692-6698. doi:10.1158/0008-5472.CAN-06-0801
[20]	T. Saito, M. Nishimura, H. Yamasaki and R. Kudo, “Hypermethylation in Promoter Region of E-cadherin Gene Is Associated with Tumor Differentiation and Myometrial Invasion in Endometrial Cancer,” Cancer, Vol. 97, No. 4, 2003, pp. 1002-1009. doi:10.1002/cncr.11157
[21]	T. Z. Yi, J. Guo, L. Zhou, X. Chen, R. R. Mi, Q. X. Qu, J. H. Zheng and L. Zhai, “ Prognotic Value of E-cadherin Expression and CDH1 Promoter Hypermethylation in Patients with Endometrial Cancer,” Cancer Investigation, Vol. 29, No. 1, 2011, pp. 86-92. doi:10.3109/07357907.2010.512603
[22]	M. Daskalakis, T. T. Nguyen, C. Nguyen, et al., “Demethylation of a Hypermethylated P15/INK4B Gene in Patients with Myelodysplastic Syndrome by 5-Aza-2’-Deoxycytidine [Decitabine] Treatment,” Blood, Vol. 100, No. 8, 2002, pp. 2957-2964. doi:10.1182/blood.V100.8.2957
[23]	J. P. Issa, G. Garcia-Manero, F. J. Giles, et al., “Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-aza-2’-Deoxycytidine [Decitabine] in Hematopoietic Malignancies,” Blood, Vol. 103, No. 5, 2003, pp. 1635-1640. doi:10.1182/blood-2003-03-0687
[24]	A. Satoh, M. Toyota, F. Itoh, et al., “Epigenetic Inactivation of CHFR and Sensitivity to Microtubule Inhibitors in Gastric Cancer,” Cancer Research, Vol. 63, No. 24, 2003, pp. 8606-8613.
[25]	D. M. Scolnick and T. D. Halazonetis, “CHFR Defines a Mitotic Stress Checkpoint That Delays Entry into Meta-phase,” Nature, Vol. 406, No. 6794, 2000, pp. 430-435. doi:10.1038/35019108
[26]	D. Kang, J. Chen, J. Wong and G. Fang, “The Checkpoint Protein CHFR Is a Ligase That Ubiquitinates Plk1 and Inhibits Cdc2 at the G2 to M Transition,” Journal of Cell Biology, Vol. 156, No. 2, 2002, pp. 249-259. doi:10.1083/jcb.200108016
[27]	X. Yu, K. Minter-Dykhouse, L. Malureanu, et al., “CHFR Is Required for Tumor Suppression and Aurora A Regulation,” Nature Genetics, Vol. 37, No. 4, 2005, pp. 401-406. doi:10.1038/ng1538
[28]	K. Ogi, M. Toyota, H. Mita, et al., “Small Interfering RNA-Induced CHFR Silencing Sensitizes Oral Squamous Cell Cancer Cells to Microtubule Inhibitors,” Cancer Biology & Therapy, Vol. 4, No. 7, 2005, pp. 773-780. doi:10.4161/cbt.4.7.1896
[29]	K. Banno, M. Yanokura, M. Kawaguchi, et al., “Epigenetic Inactivation of the CHFR Gene in Cervical Cancer Contributes to Sensitivity to Taxanes,” International Journal of Oncology, Vol. 31, No. 4, 2007, pp. 713-720.
[30]	Y. Koga, Y. Kitajima, A. Miyoshi, K. Sato, S. Sato and K. Miyazaki, “The Significance of Aberrant CHFR Methylation for Clinical Response to Microtubule Inhibitors in Gastric Cancer,” Journal of Gastroenterology, Vol. 41, No. 2, 2006, pp. 133-139. doi:10.1007/s00535-005-1732-7
[31]	Y. Muraki, K. Banno, M. Yanokura, et al., “Epigenetic DNA Hypermethylation: Clinical Applications in Endometrial Cancer (Review),” Oncology Reports, Vol. 22, No. 5, 2009, pp. 967-972.